Pharma News

Colorectal cancer is one of the most common types of cancer in the Western world and a leading cause of cancer-related deaths. Age, diet and lifestyle are known risk factors. However, in most cases we still lack a precise understanding of what triggers the disease.

In recent years, researchers have increasingly turned their attention to the ecosystem of the gut – the vast community of bacteria, viruses and other microorganisms that live there.

Hygiene in everyday items that touch the body—such as clothing, masks, and toothbrushes—is critically important. The underlying principle of how graphene selectively eliminates only bacteria has now been revealed. A KAIST research team has presented the potential for a next-generation antibacterial material that is safe for the human body and capable of replacing antibiotics.

In a move that has sent shockwaves across the global pharmaceutical industry, Sun Pharmaceutical Industries Limited has announced its biggest-ever acquisition, buying Organon & Co. in a massive USD 11.75 billion all-cash deal.
This isn’t just another corporate transaction. It’s a statement. A signal that Indian pharma is no longer playing catch-up, it’s ready to lead.

Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, successfully organized an insightful webinar entitled “Role of Artificial Intelligence in Pharmacy Careers & IT Impact”; jointly in collaboration with the Indian Pharmaceutical Association (IPA) - Hospital Pharmacy Division and RISE Trainings, Bengaluru. 

Cipla Limited and its wholly owned subsidiary Cipla USA Inc., announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation from the United States Food and Drug Administration (USFDA). It is the first AB–rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline.

Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher program.

Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular ’keyhole’, in the TRPM3 ion channel, a crucial sensor in pain signaling. TRPM3 is also linked to rare neurodevelopmental disorders and epilepsy. In a recent study published in Nature Communications, the researchers found that even the slightest change in this keyhole can radically switch the channel’s behavior, explaining how certain mutations can flip the effects of drugs.